| FUSION-DISTRIBUTION-GROUP |
FUSION-DISTRIBUTION-GROUP |
85%
|
ed on December 5, 2024 (the “December 5 NR”) as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the “March 7 NR”). The Company issued 2,420 Debenture Units (as … |
| VIBRANT-PHARMA-INC |
VIBRANT-PHARMA-INC |
85%
|
is Pharma Inc. (“ Corealis ”), Adgyl Lifesciences (“ Adgyl ”) and Vibrant Pharma Inc. (“ Vibrant Pharma ”). Each of Ingenu, BioPharma, Erythro, Corealis, Adgyl and Vibrant Pharma are CROs that, in th… |
| FIISP |
FIISP |
72%
|
may have resulted, and may continue to result, in speculation regarding future appreciation in the value of cryptocurrencies, inflating their market prices and making those market prices more volatil… |
| FIISP |
FIISP |
72%
|
Reciprocal relationship from FIISP graph: Reciprocal relationship from QNTM graph: may have resulted, and may continue to result, in speculation regarding future appreciation in the value of cryptocu… |
| GME |
GameStop Corp. |
72%
|
ed on December 5, 2024 (the “December 5 NR”) as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the “March 7 NR”). The Company issued 2,420 Debenture Units (as … |
| GME |
GameStop Corp. |
72%
|
Reciprocal relationship from GME graph: Reciprocal relationship from QNTM graph: Reciprocal relationship from GME graph: Reciprocal relationship from QNTM graph: ed on December 5, 2024 (the “December… |
| GNS |
Genius Group Limited |
72%
|
ed on December 5, 2024 (the “December 5 NR”) as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the “March 7 NR”). The Company issued 2,420 Debenture Units (as … |
| GNS |
Genius Group Limited |
72%
|
Reciprocal relationship from GNS graph: Reciprocal relationship from QNTM graph: Reciprocal relationship from GNS graph: Reciprocal relationship from QNTM graph: Reciprocal relationship from GNS grap… |
| PNPNF |
Power Metallic Mines Inc. |
72%
|
Item 4. Information on the Company. – B. Business Overview - Products and Sales ” and the 2025 Annual MD&A attached hereto as Exhibit 15.1. 79 Table of Contents D. Trend Information The following tre… |
| PNPNF |
Power Metallic Mines Inc. |
72%
|
Reciprocal relationship from PNPNF graph: Reciprocal relationship from QNTM graph: Reciprocal relationship from PNPNF graph: Reciprocal relationship from QNTM graph: Item 4. Information on the Compan… |
| BITGO-PRIME-LLC |
BITGO-PRIME-LLC |
62%
|
arm our competitive position. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known… |
| CELLY-NUTRITION-CORP |
CELLY-NUTRITION-CORP |
62%
|
ed on December 5, 2024 (the “December 5 NR”) as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the “March 7 NR”). The Company issued 2,420 Debenture Units (as … |
| CELLY-U-S-NUTRITION-CORP |
CELLY-U-S-NUTRITION-CORP |
62%
|
autioned not to place undue reliance on forward-looking statements as the Company's actual results may differ materially and adversely from those expressed or implied. The Company has made certain as… |
| CEO-PRESIDENT-CO |
CEO-PRESIDENT-CO |
62%
|
Item 4. Information on the Company. – B. Business Overview - Products and Sales ” and the 2025 Annual MD&A attached hereto as Exhibit 15.1. 79 Table of Contents D. Trend Information The following tre… |
| CHILEAN-METALS-INC |
CHILEAN-METALS-INC |
62%
|
Item 4. Information on the Company. – B. Business Overview - Products and Sales ” and the 2025 Annual MD&A attached hereto as Exhibit 15.1. 79 Table of Contents D. Trend Information The following tre… |
| COREALIS-PHARMA-INC |
COREALIS-PHARMA-INC |
62%
|
Item 3. Key information - D. Risk Factors ” in or incorporated by reference in this Annual Report or unforeseen events. While the Company believes it has the skills and resources necessary to accompl… |
| DIRECTOR-STOCK-TREND-CAPITAL-INC |
DIRECTOR-STOCK-TREND-CAPITAL-INC |
62%
|
Item 4. Information on the Company. – B. Business Overview - Products and Sales ” and the 2025 Annual MD&A attached hereto as Exhibit 15.1. 79 Table of Contents D. Trend Information The following tre… |
| ERYTHRO-PHARMA-LTD |
ERYTHRO-PHARMA-LTD |
62%
|
Item 3. Key information - D. Risk Factors ” in or incorporated by reference in this Annual Report or unforeseen events. While the Company believes it has the skills and resources necessary to accompl… |
| FSD-STRATEGIC-INVESTMENTS-INC |
FSD-STRATEGIC-INVESTMENTS-INC |
62%
|
100.00 100.00 FV Pharma Inc. Canada 100.00 100.00 100.00 Lucid Psycheceuticals Inc. Canada 100.00 100.00 100.00 FSD Strategic Investments Inc. Canada 100.00 100.00 100.00 FSD Pharma Australia Pty Ltd… |
| FV-PHARMA-INC |
FV-PHARMA-INC |
62%
|
100.00 100.00 FV Pharma Inc. Canada 100.00 100.00 100.00 Lucid Psycheceuticals Inc. Canada 100.00 100.00 100.00 FSD Strategic Investments Inc. Canada 100.00 100.00 100.00 FSD Pharma Australia Pty Ltd… |
| GBB-DRINK-LAB-INC |
GBB-DRINK-LAB-INC |
62%
|
ment, the Company shall pay a yearly license maintenance fee of C$ 50,000 until the first commercial sale of a product is made. Under the agreement the Company is committed to minimum milestone payme… |
| HUGE-BIOPHARMA-AUSTRALIA-PTY-LTD |
HUGE-BIOPHARMA-AUSTRALIA-PTY-LTD |
62%
|
100.00 100.00 FV Pharma Inc. Canada 100.00 100.00 100.00 Lucid Psycheceuticals Inc. Canada 100.00 100.00 100.00 FSD Strategic Investments Inc. Canada 100.00 100.00 100.00 FSD Pharma Australia Pty Ltd… |
| LUCID-PSYCHECEUTICALS-INC |
LUCID-PSYCHECEUTICALS-INC |
62%
|
100.00 100.00 FV Pharma Inc. Canada 100.00 100.00 100.00 Lucid Psycheceuticals Inc. Canada 100.00 100.00 100.00 FSD Strategic Investments Inc. Canada 100.00 100.00 100.00 FSD Pharma Australia Pty Ltd… |
| MALONE-WEALTH-VENTURES-LLC |
MALONE-WEALTH-VENTURES-LLC |
62%
|
ed on December 5, 2024 (the “December 5 NR”) as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the “March 7 NR”). The Company issued 2,420 Debenture Units (as … |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
autioned not to place undue reliance on forward-looking statements as the Company's actual results may differ materially and adversely from those expressed or implied. The Company has made certain as… |
| STREET-CAPITAL-INC |
STREET-CAPITAL-INC |
62%
|
Item 4. Information on the Company. – B. Business Overview - Products and Sales ” and the 2025 Annual MD&A attached hereto as Exhibit 15.1. 79 Table of Contents D. Trend Information The following tre… |
| UNBUZZD-WELLNESS-INC |
UNBUZZD-WELLNESS-INC |
62%
|
100.00 100.00 FV Pharma Inc. Canada 100.00 100.00 100.00 Lucid Psycheceuticals Inc. Canada 100.00 100.00 100.00 FSD Strategic Investments Inc. Canada 100.00 100.00 100.00 FSD Pharma Australia Pty Ltd… |
